These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33220153)

  • 1. Assessment of quality of life in Gaucher disease: A methodological approach.
    Zizemer VS; Nalin T; Schwartz IVD; Vanz AP
    Mol Genet Genomic Med; 2021 Jan; 9(1):e1549. PubMed ID: 33220153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme Replacement Therapy in a Gaucher Family.
    Erdem N; Buran T; Berber I; Aydogdu I
    J Natl Med Assoc; 2018 Aug; 110(4):330-333. PubMed ID: 30126557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competing for the treasure in exceptions.
    Cox TM
    Am J Hematol; 2013 Mar; 88(3):163-5. PubMed ID: 23400870
    [No Abstract]   [Full Text] [Related]  

  • 4. Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage?
    Brunel-Guitton C; Rivard GE; Galipeau J; Alos N; Miron MC; Therrien R; Mitchell G; Lapierre G; Lambert M
    Mol Genet Metab; 2009 Feb; 96(2):73-6. PubMed ID: 19083253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gaucher disease.
    Mignot C; Gelot A; De Villemeur TB
    Handb Clin Neurol; 2013; 113():1709-15. PubMed ID: 23622393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel heterozygous c.798C>G and c.1040T>G mutations in the GBA1 gene are associated with a severe phenotype of Gaucher disease type 1.
    Machaczka M; Klimkowska M
    Ann Hematol; 2014 Oct; 93(10):1787-9. PubMed ID: 24577513
    [No Abstract]   [Full Text] [Related]  

  • 7. [Gaucher disease: enzyme replacement treatment initiated at pediatric age; 20-year experience].
    Vitoria Miñana I; Dalmau Serra J
    An Pediatr (Barc); 2016 Jun; 84(6):343-6. PubMed ID: 26724255
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
    Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: a case report.
    Martinez-Redondo C; Ortuño FJ; Lozano ML; Jerez A; del Mar Osma M; Giraldo P; Vicente V
    J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S265-7. PubMed ID: 19562501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy.
    Elstein D; Abrahamov A; Altarescu G; Zimran A
    Blood Cells Mol Dis; 2013 Feb; 50(2):140. PubMed ID: 23085428
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapy of adult Gaucher disease.
    Schmitz J; Poll LW; vom Dahl S
    Haematologica; 2007 Feb; 92(2):148-52. PubMed ID: 17296562
    [No Abstract]   [Full Text] [Related]  

  • 12. Breastfeeding in Gaucher disease: is enzyme replacement therapy safe?
    Dornelles AD; de Oliveira Netto CB; Vairo F; de Mari JF; Tirelli KM; Schwartz IV
    Clin Ther; 2014 Jun; 36(6):990-1. PubMed ID: 24768190
    [No Abstract]   [Full Text] [Related]  

  • 13. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Picture in clinical hematology no. 67].
    Rinsho Ketsueki; 2013 Nov; 54(11):2023. PubMed ID: 24305533
    [No Abstract]   [Full Text] [Related]  

  • 15. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations.
    Charrow J; Andersson HC; Kaplan P; Kolodny EH; Mistry P; Pastores G; Prakash-Cheng A; Rosenbloom BE; Scott CR; Wappner RS; Weinreb NJ
    J Pediatr; 2004 Jan; 144(1):112-20. PubMed ID: 14722528
    [No Abstract]   [Full Text] [Related]  

  • 16. [Intestinal manifestation of type 1 Gaucher disease despite enzyme replacement therapy].
    Gómez Delgado E; Reina Campos F; Gavilán Carrasco F; Leo Carnerero E
    Med Clin (Barc); 2008 Nov; 131(19):758-9. PubMed ID: 19091209
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacologic chaperoning as a strategy to treat Gaucher disease.
    Yu Z; Sawkar AR; Kelly JW
    FEBS J; 2007 Oct; 274(19):4944-50. PubMed ID: 17894779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.
    Serratrice C; Bengherbia M; Alessandrini M; Grosbois B; Camou F; Pers YM; Bismuth M; Marie I; Belmatoug N; Berger M;
    Blood Cells Mol Dis; 2014; 53(1-2):94-6. PubMed ID: 24411065
    [No Abstract]   [Full Text] [Related]  

  • 19. Vitreous Changes in Gaucher Disease Type 3.
    Promelle V; Salvarinova R; Lyons CJ
    Ophthalmology; 2020 Jun; 127(6):813. PubMed ID: 32444021
    [No Abstract]   [Full Text] [Related]  

  • 20. Enzyme replacement therapy for mild patients with Gaucher disease.
    Zimran A; Ilan Y; Elstein D
    Am J Hematol; 2009 Apr; 84(4):202-4. PubMed ID: 19229987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.